Parkside Financial Bank & Trust Acquires 1,249 Shares of Eli Lilly and Company $LLY

Parkside Financial Bank & Trust lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 18.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 7,853 shares of the company’s stock after purchasing an additional 1,249 shares during the period. Eli Lilly and Company comprises 0.7% of Parkside Financial Bank & Trust’s holdings, making the stock its 29th biggest position. Parkside Financial Bank & Trust’s holdings in Eli Lilly and Company were worth $6,121,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Cypress Capital Management LLC WY lifted its stake in shares of Eli Lilly and Company by 35.4% during the 2nd quarter. Cypress Capital Management LLC WY now owns 111 shares of the company’s stock worth $87,000 after purchasing an additional 29 shares during the last quarter. Aviva PLC grew its stake in Eli Lilly and Company by 8.6% in the second quarter. Aviva PLC now owns 622,207 shares of the company’s stock valued at $485,029,000 after purchasing an additional 49,352 shares during the last quarter. ZEGA Investments LLC raised its holdings in Eli Lilly and Company by 278.3% in the second quarter. ZEGA Investments LLC now owns 6,476 shares of the company’s stock worth $5,048,000 after purchasing an additional 4,764 shares in the last quarter. Prospera Financial Services Inc lifted its position in shares of Eli Lilly and Company by 64.9% during the second quarter. Prospera Financial Services Inc now owns 44,963 shares of the company’s stock valued at $35,061,000 after buying an additional 17,702 shares during the last quarter. Finally, RWA Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 49.0% in the 2nd quarter. RWA Wealth Partners LLC now owns 64,533 shares of the company’s stock valued at $50,305,000 after buying an additional 21,231 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.5%

NYSE LLY opened at $923.35 on Friday. The company has a market capitalization of $872.92 billion, a PE ratio of 60.35, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a fifty day moving average of $799.97 and a 200 day moving average of $775.76. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $955.46. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period last year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 29.35%.

Insider Buying and Selling

In other news, Director Gabrielle Sulzberger acquired 117 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This represents a 2.14% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have acquired 4,314 shares of company stock worth $2,766,929. 0.14% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on LLY shares. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research note on Sunday, August 17th. Guggenheim reaffirmed a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $960.88.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.